
The Overlooked Symptom That Makes Depression So Hard to Treat
Psychologists call it anhedonia, from Greek roots meaning "without pleasure." (It's the opposite of "hedonism," the pursuit of pleasure.)
You may not be familiar with the term (unless you're a big Annie Hall fan – it was the film's original title), but anhedonia is one of two core features, alongside persistent low mood, in depression's long list of symptoms. It's also one of the hardest to treat, and a significant risk factor for battling lifelong depression.
But new research offers encouragement. Scientists are uncovering anhedonia's little-understood causes, opening doors to new treatments like exploring the meaning of life during therapy or identifying brain biomarkers that predict the most effective medications.
Though the symptom is notoriously stubborn, really tuning into your anhedonia can set you on a path to overcoming it, experts say – and lessen the chances that depression will recur.
"We see it all the time in our clinics, where patients are significantly struggling with the lack of motivation and the lack of experiencing pleasurable activities that they used to enjoy," said Majd Al-Soleiti, MD, a resident psychiatrist at the Mayo Clinic in Rochester, Minnesota, and author of a recent anhedonia study review. "So it's a clinical problem, but also we have gained a lot of knowledge in terms of how it may explain so many problems that we have that go beyond depression."
Cracking the Mystery of Anhedonia
Anhedonia shows up in a broad range of health conditions, including substance use disorders, eating disorders, and neurodegenerative diseases like Alzheimer's and Parkinson's. An estimated 35% of people with epilepsy have anhedonia, plus nearly 20% of people who've had strokes, and 25% of those with chronic pain. Among depression patients, up to 70% have anhedonia.
We've all learned to tolerate a lack of pleasure in certain situations, like traffic jams and toddler tantrums. Anhedonia is different – it persists, and it's the result of the brain's reward processing circuitry malfunctioning.
"People need to take anhedonia very seriously because it can have very negative consequences," including a heightened risk of suicide, said Diego Pizzagalli, PhD, an anhedonia expert and founding director of the Noel Drury, MD, Institute for Translational Depression Discoveries at the University of California, Irvine.
Neuroimaging has refined the understanding of anhedonia – in particular, that there are two main subtypes: consummatory and anticipatory.
Knowing the type of anhedonia can help identify the most effective treatment.
Before and After: Anticipation and Consumption
Most of us get excited knowing that something good is about to happen – you're going to eat your favorite meal or go on a trip. This is the anticipatory reward processing effect. When anticipatory anhedonia sets in, the pleasure and excitement aren't there. Consummatory anhedonia, by contrast, refers to a lack of pleasure during activities or interests that were once enjoyable.
In both cases, imaging shows that the brain no longer responds as though it is expecting or experiencing a reward.
"When someone is depressed, they will often stop meeting up with friends as often, or they'll stop doing the hobbies that they usually enjoy because those kinds of things just don't feel as enjoyable or they don't feel as interesting as they used to," said Jennifer N. Bress, PhD, a psychologist at Weill Cornell Medicine in New York City who researchers brain activity linked to depression and treatment response.
Bress's research shows that people with anhedonia have differences "on a neural level" – meaning the symptom is linked to changes in the way neurons (brain cells) communicate using electrical and chemical signals.
"The brain's reactivity to rewards also decreases," said Bress.
A classic experiment demonstrates this. It's a guessing game where people being researched can win 50 cents for each correct answer, or lose 25 cents if they're wrong.
"People have less electrical activity in their brain in response to winning money when they're depressed versus when they're not," Bress said. And yes, they really give people 50 cents – or take a quarter away. "There's something about knowing that this is real and that they will actually win something that's important to getting a robust response."
What that means outside the lab: When you're working to overcome anhedonia, it's important that the rewards you anticipate or experience be real – because your brain responds more strongly when stakes are tangible.
Treatments That Help
One of the most effective treatments for anhedonia – whether anticipatory or consummatory – is a therapy called "behavioral activation," said Pizzagalli.
Behavioral activation takes a step-by-step approach to help patients get back to activities they once enjoyed. This includes scheduling each step leading up to the activity, such as deciding who will join you, and organizing the smallest logistics in advance. Therapists help clients overcome barriers along the way.
New potential therapy approaches are emerging. One is "positive affect" treatment, where people work to focus more on positive emotions with the added goal of feeling fewer negative emotions. The idea is that increasing positive emotions can heighten reward sensitivity – helping the brain break out of its anhedonic cycles. Other research suggests that therapies focused on identity, purpose, and social connection may help by boosting a person's "meaning in life," which may in turn reduce anhedonia.
Here's the theory behind why these therapies work: With anhedonia, brain connections in reward processing weaken when people disengage from their usual activities and interests.
"You end up in this sort of feedback loop where you become even more depressed and feel even less like doing things," Bress said, "so you get even fewer opportunities for rewards, which in turn leads to becoming even more depressed."
Ultimately, the brain becomes less responsive to rewards.
Behavioral activation gives patients "more opportunities to be exposed to these rewarding outcomes," she said, which "may help to strengthen some of these connections in the brain that help people respond in a healthy way to rewarding experiences."
Antidepressants tend not to work as well for anhedonia, particularly for the most severe cases, research shows. Still, there is hope for the future, as researchers develop a more detailed understanding of what is happening in the brain. Pizzagalli's team is studying brain biomarkers that may help predict which medications will work well for a particular person, laying the groundwork for a personalized approach. But for now, drugmakers have yet to develop a medication to specifically treat anhedonia, he said.
One promising contender is ketamine, which has been shown to rapidly reduce anhedonia and likely impacts the brain's functional connections. Al-Soleiti's recent paper also mentioned transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT) as being notably effective in treating anticipatory anhedonia.
Also helpful is simply improving diet and lifestyle, since these changes can reduce inflammation and stress, which both are linked to anhedonia, Pizzagalli said.
Weighing Your Options
While many unanswered questions remain in the science of anhedonia, researchers do know that the two types affect separate areas of the brain. While both anticipatory and consummatory anhedonia have been linked to depression, the association with anticipatory anhedonia has been demonstrated more consistently.
"You could have no problem actually enjoying things that you might like – say you watch a funny video and really enjoy it," Bress said. "But you may have a lot of trouble with the anticipatory piece or the motivational piece. You might notice it's really hard to actually get yourself to turn on the video, or it might be that you really enjoy seeing your friends once you go out, but it might be hard to push yourself to actually make that plan and go meet up with them at the coffee shop."
For therapy approaches, treatment usually involves weekly sessions for anywhere from two to six months. Some of Bress's clients have shown improvement within just a couple of weeks. Even if past treatments haven't worked, Pizzagalli urged people not to give up. Most therapists are trained in more than one type of therapy, so if you are considering therapy, ask if they use behavioral activation therapy or another approach specific to anhedonia.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Former FDA chief challenges agency to bar certain ultraprocessed food ingredients
The former head of the US Food and Drug Administration is testing the Trump administration's commitment to 'Make America Healthy Again' with a challenge to crack down on some of the key ingredients in ultraprocessed foods. In a petition filed Wednesday, the former FDA commissioner, Dr. David Kessler, argued that the agency has the authority to declare that certain sweeteners, refined flours and other additives are not 'generally recognized as safe.' Removing that designation, known as GRAS, would force makers of ultraprocessed foods to remove products from the market and reformulate recipes — or try to prove that those ingredients are not harmful. It would be a sweeping change to the food industry and a significant shift in the Trump administration's MAHA strategy. So far, US Health and Human Services Secretary Robert F. Kennedy Jr. has relied on popular food brands to volunteer to remove artificial dyes and other additives from their products. 'Kessler has given the FDA a way to define the vast majority of ultra-processed foods. In doing so, he has handed RFK Jr a huge gift on the path to regulating these products. It's just what MAHA has asked for. I hope they take it seriously,' Marion Nestle, the Paulette Goddard professor emerita of nutrition, food studies and public health at New York University, said in an email. Kessler proposed that companies have 12 months to submit a petition to keep those food additives in their products and then go on to prove they are safe. 'It's a very appropriate, worthy step to shift the burden of proof where it belongs and have the industry meet that burden, or stop using the substances.' said Michael Taylor, a former FDA food regulator and current co-chair of the nonprofit STOP Foodborne Illness. 'It's using the GRAS tool to really drive a serious safety conversation.' HHS did not respond to a request for comment. Federal health officials announced last month that they are looking for input on how to define ultraprocessed foods, a first step in eventually setting up new regulations, which could take months to years to establish. Kessler's petition could put pressure on that ultimately lengthy timeline; the agency is required to respond to the request within 180 days. Kessler, a physician who served as FDA commissioner under presidents Bill Clinton and George H.W. Bush, and advised President Joe Biden during the Covid-19 pandemic, oversaw the agency when it began requiring nutrition labels on food products. He also spearheaded efforts for FDA to regulate tobacco in the 1990s and sees parallels to that fight. 'What was key in tobacco was finding the regulatory hook,' Kessler told CNN. 'It was about asking the right legal question that would frame the issue.' That has been the tricky part of setting up any regulatory standards for sugary and starchy foods, he said. The term ultra processed foods has resonated with the public, he said, but 'it's going to be hard to define, legally, what's in it.' But there is a pressing need to do that, he argues. The FDA allowed these ingredients under GRAS regulations four decades ago, and rates of obesity, diabetes, and heart disease have climbed in the years since, he wrote in his petition. The argument echoes Kennedy's own case for MAHA reforms to food policy. A 'brilliant' move on processed foods The petition focuses on refined flours and starches — which the body breaks down into sugars — that are subjected to food extrusion technology, including wheat, corn, tapioca, oat and potato flour. It also references refined sugars, including corn syrup, corn solids, dextrose, xylose, maltose, and high-fructose corn syrups. Finally, the petition targets any manufactured sugars, flours and starches that contain additives commonly used in today's ultraprocessed foods. Tackling the issue of too much sugar is a key to better health, experts CNN spoke with agree, but they say the real genius of Kessler's petition is his focus on additives. 'The food industry uses the emulsifiers, the stabilizers, the gels and the rest to make inexpensive, high volume, industrially processed foods,' said Christopher Gardner, director of nutrition studies at the Stanford Prevention Research Center. 'If you take those tools away from industry it's not that foods will taste bad and icky,' Gardner said. 'They won't be as addictive, as flavorful, as tasty — and industry has made these foods as manipulatively flavorful and manipulatively tasty. That's the problem.' Several food and nutrition experts heralded Kessler's petition as a bold move that would, if enacted by FDA, reshape the food industry. 'This is an important proposal that is based on the true meaning of GRAS, which would exclude the majority of foods on our grocery shelves,' said leading nutrition researcher Dr. Walter Willett, professor of epidemiology and nutrition at Harvard T.H. Chan School of Public Health and professor of medicine at Harvard Medical School in Boston. The GRAS standard, created in 1958, was originally intended to narrowly apply to commonly used ingredients in the nation's food supply, such as oil, vinegar and baking soda. Manufacturers that used those products could rely on existing research to show their safety but are supposed to file GRAS petitions for newer ingredients like refined sugars. FDA updated its system in the late 1990s — amid a backlog of petitions for new additives — allowing companies to voluntarily notify the agency that they had determined their ingredients were generally safe. A 2022 analysis conducted by the Environmental Working Group found that nearly 99% of new chemicals used in food or food packaging since 2000 were green-lit for use not by the FDA but by the food and chemical industry. During that period, food manufacturers asked the FDA's permission to introduce a new substance only 10 times, according to the analysis. Barry Popkin, the W. R. Kenan, Jr. Distinguished Professor at the Gillings School of Global Public Health in Chapel Hill, North Carolina, called Kessler's petition 'a brilliant move.' 'Knowing the FDA like he does - he's put industry in a real bind,' Popkin said. 'They have to show that without a reasonable doubt that carbohydrates, along with additives, are healthy, and do not hurt health. And that's next to impossible. 'It's the strongest play a citizen can do to affect our food supply that I've ever seen.' But Kessler's proposed changes are likely to meet significant pushback from major food brands. Michael Taylor was FDA's deputy commissioner for foods in 2015 when the agency revoked the GRAS status of partially hydrogenated oils, or trans fats, citing extensive research about their links to risks of heart disease and stroke. The agency gave companies three years to comply and remove those oils from their products. But at that time, 'the handwriting was on the wall' for industry and many companies had already stopped using those trans fats, Taylor said. 'Obviously the substances that [Kessler] is describing, it's a lot of … highly processed, fine carbohydrates, and a lot of products.' The petition lands as Trump administration officials, led by Kennedy, prepare to release their second MAHA report. While the MAHA Commission's first dispatch in June singled out potential drivers of chronic illnesses in children — including ingredients in ultraprocessed foods — its second installment is expected to lay out proposed policy changes. The report is due by Tuesday.


CNN
37 minutes ago
- CNN
Legionnaires' disease cluster in New York City rises to 73 infections and 3 deaths
New York City health officials are continuing to investigate a cluster of cases of Legionnaires' disease, a serious bacterial lung infection, that has sickened 73 people and led to three deaths. Health officials suspect the bacteria that cause the disease, Legionella, originated in a cooling tower — a device that uses water to cool large buildings and then disperses mist into the air. If the water inside becomes too warm, stagnant, or isn't properly disinfected, Legionella can grow and sicken people who inhale the mist. The disease cannot be spread from person to person. Since the first cases were announced July 25, New York City's health department said it tested 'dozens' of cooling towers in Central Harlem, where the cases were reported. Building owners with towers that tested positive in initial screenings were directed to carry out cleaning efforts, including a chemical that kills the bacteria. Although cleaning has been completed, the disease has an incubation period of two to 10 days, according to the World Health Organization. 'Anyone in these zip codes with flu-like symptoms should contact a health care provider as soon as possible,' Acting Health Commissioner Dr. Michelle Morse said in a news release on Monday. Legionnaires' disease causes flu-like symptoms, including cough, fever, headaches, muscles aches and shortness of breath. It's treatable with antibiotics, but if left untreated, it can cause shock and multi-organ failure, according to the WHO About 10% of people who get Legionnaires' die from complications of their illness, according to the US Centers for Disease Control and Prevention, and it's more dangerous for older adults and people with weakened immune systems. Around 6,000 Legionnaires' disease cases are reported each year in the United States, according to the Occupational Safety and Health Administration, but reported totals may be lower than the actual cases in part because it can be difficult to distinguish Legionnaires' disease from other types of pneumonia.
Yahoo
42 minutes ago
- Yahoo
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
- Conference Call and Webcast Today, August 7, 2025, at 4:30 p.m. ET PASADENA, Calif., August 07, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 studies. In addition, our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025, PDUFA date," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "We continue to maintain a strong balance sheet, which we believe gives us the financial resources to move multiple innovative new medicines through the clinical and regulatory process and ultimately get them to the patients who need them." Selected Recent Events Announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of Arrowhead's investigational cardiometabolic candidates in Greater China. Summary terms of the agreement include: Visirna will receive an upfront payment of $130 million from Sanofi. In addition, Visirna will be eligible to receive further milestone payments of up to $265 million upon approval of plozasiran across various indications in mainland China. Sanofi will receive an exclusive license to develop and commercialize investigational plozasiran in Greater China from Visirna Therapeutics, offering potential treatment to people living with elevated triglycerides. Earned a $100 million milestone payment from Sarepta Therapeutics when Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. Arrowhead currently expects to achieve the second enrollment target by the end of 2025, which would trigger an additional $200 million milestone payment from Sarepta. Completed enrollment in investigational plozasiran clinical studies SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions for marketing approval in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned submissions for regulatory review and potential approval to follow. The company previously submitted a New Drug Application (NDA) for plozasiran based on positive Phase 3 PALISADE study results in patients with familial chylomicronemia syndrome, which the U.S. FDA has accepted with a Prescription Drug User Fee Act (PDUFA) action date set for November 18, 2025. Dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company's investigational RNAi therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease. Zodasiran is the fourth investigational RNAi-based candidate developed by Arrowhead to reach late-stage pivotal studies, after investigational drugs plozasiran, fazirsiran (licensed to Takeda) and olpasiran (licensed to Amgen). Dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNAi therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is designed to intervene in a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies. The study initiates in otherwise healthy obese subjects using single and multiple escalating doses of ARO-ALK7 monotherapy and is expected to progress rapidly to investigate combinations of ARO-ALK7 with tirzepatide in obese patients with and without type 2 diabetes. Selected Fiscal 2025 Third Quarter Financial Results ARROWHEAD PHARMACEUTICALS, INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Three Months Ended June 30, OPERATING SUMMARY 2025 2024 (Unaudited) Revenue $ 27,767 $ — Operating Expenses: Research and development 162,368 152,431 General and administrative expenses 30,949 23,710 Total operating expenses 193,317 176,141 Operating loss (165,550 ) (176,141 ) Total other (expense) income (13,539 ) 2,164 Loss before income tax expense and noncontrolling interest (179,089 ) (173,977 ) Income tax (benefit) expense (437 ) — Net loss including noncontrolling interest (178,652 ) (173,977 ) Net loss attributable to noncontrolling interest, net of tax (3,411 ) (3,184 ) Net loss attributable to Arrowhead Pharmaceuticals, Inc. $ (175,241 ) $ (170,793 ) Net loss per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted $ (1.26 ) $ (1.38 ) Weighted-average shares used in calculating - Diluted 139,039 124,199 FINANCIAL POSITION SUMMARY June 30, 2025 September 30, 2024 (unaudited) Cash, cash equivalents and restricted cash $ 129,793 $ 102,685 Available-for-sale securities, at fair value 770,579 578,276 Total cash resources (Cash, cash equivalents and restricted cash and Available-for-sale securities, at fair value) 900,372 680,961 Other current and long-term assets 480,240 458,841 Total Assets $ 1,380,612 $ 1,139,802 Liability related to the sale of future royalties $ 360,254 $ 341,361 Credit Facility 240,332 393,183 Deferred revenue 22,979 — Other liabilities 237,241 214,195 Total Liabilities $ 860,806 $ 948,739 Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity 522,313 185,444 Noncontrolling Interest (2,507 ) 5,619 Total Noncontrolling Interest and Stockholders' Equity $ 519,806 $ 191,063 Total Liabilities, Noncontrolling Interest and Stockholders' Equity $ 1,380,612 $ 1,139,802 Shares Outstanding 138,144 124,376 Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," "continue," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, including the timing of achievement of the next ARO-DM1 milestone, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements, including our ability to achieve such milestones on projected timelines (if at all) and receive timely payment if milestones are achieved; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We disclaim any intention to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc. View source version on Contacts Arrowhead Pharmaceuticals, Anzalone, CFA626-304-3400ir@ Investors: LifeSci Advisors, LLCBrian Ritchie212-915-2578britchie@ Media: LifeSci Communications, LLCKendy Guarinoni, Ph.D.724-910-9389kguarinoni@